ORGO Q4 2019 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$338M

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$75M+17.4% YoY

Gross Profit

$54M72.7% margin

Operating Income

-$2M-2.3% margin

Net Income

-$4M-5.9% margin

EPS (Diluted)

$-0.04

QoQ Revenue Growth

+16.2%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$10M

Stock-Based Comp.

$236,000

Balance Sheet

Total Assets

$221M

Total Liabilities

$165M

Stockholders' Equity

$56M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$64M	+17.4%
Gross Profit	$54M	$46M	+17.7%
Operating Income	-$2M	-$4M	+60.8%
Net Income	-$4M	-$9M	+52.5%

Revenue Segments

Advanced Wound care

$63M85%

Surgical and Sports Medicine

$11M15%